Compare KBH & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KBH | TMDX |
|---|---|---|
| Founded | 1957 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 1994 | 2019 |
| Metric | KBH | TMDX |
|---|---|---|
| Price | $42.58 | $71.62 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 13 |
| Target Price | $52.14 | ★ $98.73 |
| AVG Volume (30 Days) | ★ 1.4M | 704.4K |
| Earning Date | 09-22-2026 | 11-02-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | ★ 2.00 | 0.61 |
| Revenue | ★ $4,547,002,000.00 | $605,494,000.00 |
| Revenue This Year | N/A | $22.57 |
| Revenue Next Year | $2.20 | $17.85 |
| P/E Ratio | ★ $21.65 | $115.67 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $40.92 | $60.11 |
| 52 Week High | $67.57 | $156.00 |
| Indicator | KBH | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 34.09 | 34.83 |
| Support Level | N/A | $66.64 |
| Resistance Level | $58.83 | $79.60 |
| Average True Range (ATR) | 1.25 | 3.68 |
| MACD | 0.06 | -0.92 |
| Stochastic Oscillator | 26.33 | 15.25 |
KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.